Ocular Therapeutix, Inc.
OCULDrugs in Pipeline
15
Phase 3 Programs
9
Upcoming Catalysts
4
Next Catalyst
Apr 29, 2026
11wMarket Overview
Stock performance and market intelligence
4 upcoming, 1 past
Aflibercept Phase 3 Results Expected
Primary completion for Aflibercept trial (NCT06223958) in Neovascular Age-Related Macular Degeneration
SourceOTX-TKI (axitinib implant) Phase 3 Results Expected
Primary completion for OTX-TKI (axitinib implant) trial (NCT06223958) in Neovascular Age-Related Macular Degeneration
Sourced-MAPPS Phase 2 Results Expected
Primary completion for d-MAPPS trial (NCT06852768) in oGHVD
SourceAflibercept Phase 3 Results Expected
Primary completion for Aflibercept trial (NCT06495918) in Neovascular Age-related Macular Degeneration
SourceAI Predictions & Institutional Flow
Machine learning insights and smart money movement
FDA Submissions
Pending NDA/BLA submissions with predicted PDUFA dates
Drug Pipeline
Clinical development programs and drug candidates
Aflibercept
Neovascular Age-related Macular Degeneration
OTX-TKI (axitinib implant)
Neovascular Age-Related Macular Degeneration
Single intravitreal injection of axitinib hydrogel implant followed by a mock (sham) injection procedure at Week 24
Non-Proliferative Diabetic Retinopathy
Ophthalmic Insert
Open Angle Glaucoma and Ocular Hypertension
Dextenza Ophthalmic Insert
Cataract
Travoprost
Open Angle Glaucoma
Dexamethasone, 0.4mg
Allergic Conjunctivitis
Dexamethasone
Post-Surgical Ocular Pain
Punctum Plug
Post Ocular Surgical Inflammation and Pain
OTX-TP
Glaucoma
OTX-TIC low dose Travoprost Intracameral Implant
Open Angle Glaucoma
OTX-CSI
Dry Eye Disease
OTX-DED
Dry Eye
OTX-DP (Dexamethasone punctum plug)
Ocular Inflammation and Pain
Controlled Insertion
Dry Eye Syndromes
| Drug Name | Phase | Indication | Designations |
|---|---|---|---|
Aflibercept | Phase 3 | Neovascular Age-related Macular Degeneration | - |
OTX-TKI (axitinib implant) | Phase 3 | Neovascular Age-Related Macular Degeneration | - |
Single intravitreal injection of axitinib hydrogel implant followed by a mock (sham) injection procedure at Week 24 | Phase 3 | Non-Proliferative Diabetic Retinopathy | - |
Ophthalmic Insert | Phase 3 | Open Angle Glaucoma and Ocular Hypertension | - |
Dextenza Ophthalmic Insert | Phase 3 | Cataract | - |
Travoprost | Phase 3 | Open Angle Glaucoma | - |
Dexamethasone, 0.4mg | Phase 3 | Allergic Conjunctivitis | - |
Dexamethasone | Phase 3 | Post-Surgical Ocular Pain | - |
Punctum Plug | Phase 3 | Post Ocular Surgical Inflammation and Pain | - |
OTX-TP | Phase 2 | Glaucoma | - |
OTX-TIC low dose Travoprost Intracameral Implant | Phase 2 | Open Angle Glaucoma | - |
OTX-CSI | Phase 2 | Dry Eye Disease | - |
OTX-DED | Phase 2 | Dry Eye | - |
OTX-DP (Dexamethasone punctum plug) | Phase 2 | Ocular Inflammation and Pain | - |
Controlled Insertion | Phase 2 | Dry Eye Syndromes | - |
Regulatory & News
Approvals, filings, and latest developments